The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo

Journal of Steroid Biochemistry and Molecular Biology

Volumn 114, Issue 1-2, 2009, Pages 90-95

  Murphy, Leigh C ^a   Skliris, Georgios P ^a   Rowan, Brian G ^b   Al Dhaheri, Mariam ^b   Williams, Christopher ^b   Penner, Carla ^a   Troup, Sandy ^a   Begic, Sanela ^a   Parisien, Michelle ^a   Watson, Peter H ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Endocrine therapy; Estrogen receptor; Immunohistochemistry; Phosphorylation; Tissue collection time; Tissue microarrays; Validation

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P90; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; PHOSPHORYLATION; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BIOPSY; WESTERN BLOTTING;

BIOPSY; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; PHOSPHORYLATION; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 62949213226     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.01.017     Document Type: Article

References (27)

1. Harvey J., Clark G., Osborne C., and Allred D. Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17 5 (1999) 1474-1481
2. Osborne C. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51 (1998) 227-238
3. Osborne C. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339 (1998) 1609-1618
4. Osborne C., and Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 23 (2005) 1616-1622
5. Lannigan D. Estrogen receptor phosphorylation. Steroids 68 1 (2003) 1-9
6. Weigel N., and Moore N. Steroid receptor phopshorylation: a key modulator of multiple receptor functions. Mol. Endocrinol. 21 (2007) 2311-2319
7. Murphy L., and Watson P. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr. Relat. Cancer 13 (2006) 327-334
8. Al-Dhaheri M., and Rowan B. Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor alpha. Nucl. Recept. Signal. 4 (2006) e007 (Epub April 28)
9. Williams C., Smith C.L., and Rowan B.G. Identification of four novel phosphorylation sites in estrogen receptor α: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. The Endocrine Society's 89th Annual Meeting. Toronto, Canada (2007) P2-P258
10. G. Skliris, B. Rowan, M. Al-Dhaheri, C. Williams, S. Troup, S. Begic, M. Parisien, P. Watson, L. Murphy, Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays (TMA) of ERα positive human breast carcinomas, Breast Cancer Res. Treat., 2008 Dec 23. [Epub ahead of print].
11. Atsriku C., Britton D., Held J., Schilling B., Scott G., Gibson B., Benz C., and Baldwin M. Systematic mapping of posttranslational modifications in human estrogen receptor alpha, with emphasis on novel phosphorylation sites. Mol. Cell. Proteomics November (3) (2008) (Epub ahead of print)
12. Murphy L., Weitsman G., Skliris G., Teh E., Li L., Peng B., Davie J., Ung K., Niu Y., Troup S., et al. Potential role of estrogen receptor alpha phosphorylation at serine 118 in human breast cancer in vivo. J. Steroid Biochem. Mol. Biol. 102 (2006) 139-146
13. Schiff R., Massarwah S., Shou J., Bharwani L., Arpino G., Rimawi M., and Osborne C. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother. Pharmacol. 56 Suppl. 1 (2005) s10-s20
14. Murphy L., Niu Y., Snell L., and Watson P. Phospho-serine-118 estrogen receptor-alpha expression in primary human breast tumors in vivo is associated with better disease outcome in women treated with tamoxifen. Clin. Cancer Res. 10 17 (2004) 5902-5906
15. Murphy L.C., Cherlet T., Adeyinka A., Niu Y., Snell L., and Watson P. Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin. Cancer Res. 10 (2004) 1354-1359
16. Gee J., Robertson J., Gutteridge E., Ellis I., Pinder S., Rubini M., and Nicholson R. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S99-S111
17. Sarwar N., Kim J., Jiang J., Peston D., Sinnett H., Madden P., Gee J., Nicholson R., Lykkesfeldt A., Shousha S., et al. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr. Relat. Cancer 13 (2006) 851-861
18. Bergqvist J., Elmberger G., Ohd J., Linderholm B., Bjohle J., Hellborg H., Nordgren H., Borg A., Skoog L., and Bergh J. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur. J. Cancer 42 (2006) 1104-1112
19. Jiang J., Sarwar N., Peston D., Kulinskaya E., Shousha S., Coombes R., and Ali S. Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res. 13 (2007) 5769-5776
20. C. Holm, M. Kok, R. Michalides, R. Fles, R. Koornstra, J. Wesseling, M. Hauptmann, J. Neefjes, J. Peterse, O. Stål, et al., Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer, J. Pathol. (September (23)) (2008) (Epub ahead of print).
21. Chen D., Washbrook E., Sarwar N., Bates G., Pace P., Thirunuvakkarasu V., Taylor J., Epstein R., Fuller-Pace F., Egly J., et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21 32 (2002) 4921-4931
22. Weitsman G., Li L., Skliris G., Davie J., Ung K., Curtis-Snell L., Tomes L., Watson P., and Murphy L. Estrogen receptor-alpha phosphorylated at serine 118 is present at the promoters of estrogen-regulated genes and is not altered due to Her2 over-expression. Cancer Res. 66 (2006) 10162-10170
23. Barnes R., Parisien M., Murphy L., and Watson P. Influence of evolution in tumor biobanking on the interpretation of ranslational research. Cancer Epidemiol. Biomarkers Prev. 17 12 (2008) 3344-3350
24. Yamashita H., Nishio M., Kobayashi S., Ando Y., Sugiura H., Zhang Z., Hamaguchi M., Mita K., Fujii Y., and Iwase H. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 7 (2005) R753-R764
25. Yamashita H., Nishio M., Toyama T., Sugiura H., Kondo N., Kobayashi S., Fuji Y., and Iwase H. Low phosphorylation of estrogen receptor {alpha} (ER{alpha}) serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer. Endocr. Relat. Cancer 15 (2008) 755-763
26. M. Dowsett, S. Johnston, L.A. Martin, J. Salter, M. Hills, S. Detre, M.C. Gutierrez, S.K. Mohsin, J. Shou, D.C. Allred, R. Schiff, C.K. Osborne, I. Smith, Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience, Endocr. Relat. Cancer 12 (Suppl. 1) (2005) S113-S117.
27. Yang C., Xin H., Kelley J., Spencer A., Brautigan D., and Paschal B. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol. Cell. Biol. 27 (2007) 3390-3404